The table below shows BridgeBio Pharma, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
Line item
Q1 2026
Q3 2025
Q2 2025
Q1 2025
Q3 2024
Q2 2024
Revenue
$194.51M
$120.70M
$110.56M
$116.63M
$2.73M
$2.17M
Cost of revenue
$9.94M
$6.56M
$3.65M
$2.64M
$598.00K
$598.00K
Gross profit
-
-
-
-
-
-
R&D
$126.64M
$112.87M
$111.23M
$111.43M
$120.44M
$114.69M
BBIO annual revenue (10-K history)
BridgeBio Pharma, Inc. reported annual revenue of $502.08M for fiscal year 2025. That is up 126.3% from $221.90M in fiscal 2024. Over the 7 fiscal years shown, annual revenue grew from $40.56M (FY 2019) to $502.08M. Figures come from the company's audited annual reports as filed with the SEC.
